Appendix AOperational Decisions Made in Conjunction With the U.S. Preventive Services Task Force

The following decisions were made in conjunction with the U.S. Preventive Services Task Force.

  1. Vaccination to prevent infection with HPV. The analysis is restricted to screening strategies only and does not include a strategy of vaccination to prevent infection with HPV.
  2. Adherence to screening, followup, and treatment. Adherence to screening, followup, and treatment is 100 percent for the base case.
  3. HPV DNA testing. HPV DNA testing refers to the Hybrid Capture 2 (HC2) high-risk HPV DNA test (Qiagen, Inc., Germantown, MD).
  4. Performance of colposcopy and biopsy. Colposcopy and biopsy are assumed to be 100 percent sensitive and specific.
  5. Strategies for the analysis of age at which to begin and end screening. This analysis is restricted to cytology-based strategies.